United Kingdom-based AstraZeneca has received approval from the US Food and Drug Administration (FDA) for its Tagrisso (osimertinib) as the first-line treatment for patients with metastatic non-small cell lung cancer whose tumours have epidermal growth factor receptor mutations, it was reported yesterday.
The approval is based on results from the Phase III FLAURA trial, which were revealed at the European Society of Medical Oncology 2017 Congress. The FLAURA trial compared Tagrisso to current 1st-line EGFR tyrosine kinase inhibitors (TKIs), erlotinib or gefitinib, in earlier-untreated patients with locally-advanced or metastatic EGFR-mutated (EGFRm) non-small cell lung cancer.
The product met the primary endpoint of progression-free survival. Progression-Free Survival results with Tagrisso were consistent across all pre-specified patient subgroups, including in patients with or without central nervous system metastases. Overall survival data were not mature at the time of the final Progression-Free Survival analysis. Safety data for the product in the FLAURA trial were in line with those observed in prior clinical trials.
GC Biopharma's GC1130A receives EMA Orphan Drug Designation
Guangzhou Fermion Technology's FZ008-145 IND application receives Chinese regulatory approval
Newron enrols 290 patients in schizophrenia study
Vistagen granted European patent for AV-101 to treat neuropathic pain
Alora Pharmaceuticals announces Relexxii commercial launch
IGC Pharma granted patent for Alzheimer's drug formulation
NRx Pharmaceuticals signs data agreement with Columbia University for IV Ketamine trials
Cambridge Cognition launches AQUA for automated quality assurance in CNS clinical trials
Shanghai Zhimeng Biopharma's CB03 receives US FDA orphan drug designation
Genentech's Alecensa demonstrates 76% reduction in disease recurrence risk
NRx Pharmaceuticals announces presentation at 8th Annual Dawson James Conference